DNDi Receives Goodwin Award for Its Social Entrepeneurial Approach for the Most Neglected

[ Siena, Italy; Geneva, Switzerland – May 8, 2008 ]
The University of Siena today awarded the Drugs for Neglected Diseases initiative (DNDi) with a Goodwin Award for its innovative needs-driven approach in making 2 new antimalarials available as public goods, and in engaging public and private partners worldwide, especially in neglected disease-endemic countries, to ensure that the best science is made available for those neglected patients.

A Worldwide Public Partnership Makes Available a New, Once-a-Day Fixed-Dose Combination against Malaria

[ Rio de Janeiro – April 17, 2008 ]
An innovative partnership between the Brazilian public pharmaceutical company, Farmanguinhos/Fiocruz, and the non-profit drug development organization, Drugs for Neglected Diseases initiative (DNDi), announced today that ASMQ, the new fixed-dose combination of artesunate (AS) and mefloquine (MQ), is now registered and available in Brazil.
[Português] [Español] [Français] [Italiano]

The US National Institutes of Health Awards DNDi with a 3-Year Grant Dedicated to the Development of a Low-Cost Treatment for Visceral Leishmaniasis

[ Geneva, Switzerland – November 5, 2007 ]
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has granted Drugs for Neglected Diseases initiative (DNDi) USD 2.3 million to be disbursed over 3 years for research and development that focuses on developing a low-cost formulation of amphotericin B to treat visceral leishmaniasis.

Advinus Therapeutics and DNDi Join Forces on Drug Discovery and Development for Visceral Leishmanias (Kala Azar)

[ Bangalore and Geneva October  11, 2007 ]
Advinus Therapeutics (P) Ltd. and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit R&D organization based in Geneva, Switzerland, announced today that they have formed a collaboration for discovery and development of novel therapies for visceral leishmaniasis (kala azar), a fatal infectious disease of developing countries including India.

New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available

[ Paris – March 1st, 2007 ]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) announced today that ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), will soon be available throughout sub-Saharan Africa. ASAQ is the first drug developed by the FACT (Fixed-dose, Artemisinin-based Combination Therapy) partners, managed by DNDi in partnership with sanofi-aventis.
[Français]

Waking Up Governments for Research on Neglected Diseases

[Geneva – May 16, 2006 ]
The R&D Appeal launched in June 2005 by the Drugs for Neglected Diseases initiative (DNDi), its founding partners, Oxfam, and the BIOS initiative, urges governments to take greater leadership in R&D on neglected diseases.

DFID’s funding of DNDi in the news…

[Geneva –March 9, 2006]
UK government commits £6.5 million to DNDi’s research for new medicines for neglected diseases
RealHealthNews interview with Bernard Pecoul regarding DFID funding of DNDi.

Two New Malaria Treatments Available in 2006

[ Washington , DC – December  11, 2005 ]
First medicines developed by Drugs for Neglected Diseases initiative (DNDi) will be easier to use and less expensive than current ACTs, but action is needed to make sure the treatments reach patients.

DNDi and Indian scientists collaborate in hunt for new drugs for neglected diseases

[ Delhi, India – October 4, 2005 ]
The Drugs for Neglected Diseases initiative (DNDi), a not-for-profit drug development initiative, is collaborating with the Central Drug Research Institute (CDRI) Lucknow to test their library of compounds for possible activity against parasites that cause deadly neglected diseases such as kala azar and sleeping sickness.